Clinically relevant is the fact that the AMPK activator, AICAR, which we show in this study to reduce Nox4 expression and IL-6 and IL-8 production, reduces RCC cell invasion in vitro and in ex vivo RCC cells isolated from a human clear cell carcinoma tumor. Here, IL6 is linked to renal cell carcinoma.